ERBB2 and neoplasm: With decreased incidence, rMBC patient characteristics changed by tumor marker subtype (more triple negative, fewer hormone or HER2 positive) and rMBC disease profile (> 1 metastatic site, visceral disease, or combined local/regional/distant at relapse).